300 related articles for article (PubMed ID: 21057528)
1. A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice.
Draheim KM; Hermance N; Yang Y; Arous E; Calvo J; Kelliher MA
Oncogene; 2011 Mar; 30(10):1252-60. PubMed ID: 21057528
[TBL] [Abstract][Full Text] [Related]
2. Enforced expression of E47 has differential effects on Lmo2-induced T-cell leukemias.
Goodings C; Tripathi R; Cleveland SM; Elliott N; Guo Y; Shyr Y; Davé UP
Leuk Res; 2015 Jan; 39(1):100-9. PubMed ID: 25499232
[TBL] [Abstract][Full Text] [Related]
3. Structure of the leukemia oncogene LMO2: implications for the assembly of a hematopoietic transcription factor complex.
El Omari K; Hoosdally SJ; Tuladhar K; Karia D; Vyas P; Patient R; Porcher C; Mancini EJ
Blood; 2011 Feb; 117(7):2146-56. PubMed ID: 21076045
[TBL] [Abstract][Full Text] [Related]
4. Expression of the leukemia oncogene Lmo2 is controlled by an array of tissue-specific elements dispersed over 100 kb and bound by Tal1/Lmo2, Ets, and Gata factors.
Landry JR; Bonadies N; Kinston S; Knezevic K; Wilson NK; Oram SH; Janes M; Piltz S; Hammett M; Carter J; Hamilton T; Donaldson IJ; Lacaud G; Frampton J; Follows G; Kouskoff V; Göttgens B
Blood; 2009 Jun; 113(23):5783-92. PubMed ID: 19171877
[TBL] [Abstract][Full Text] [Related]
5. Identification of a TAL1 target gene reveals a positive role for the LIM domain-binding protein Ldb1 in erythroid gene expression and differentiation.
Xu Z; Huang S; Chang LS; Agulnick AD; Brandt SJ
Mol Cell Biol; 2003 Nov; 23(21):7585-99. PubMed ID: 14560005
[TBL] [Abstract][Full Text] [Related]
6. Assembly of the oncogenic DNA-binding complex LMO2-Ldb1-TAL1-E12.
Ryan DP; Duncan JL; Lee C; Kuchel PW; Matthews JM
Proteins; 2008 Mar; 70(4):1461-74. PubMed ID: 17910069
[TBL] [Abstract][Full Text] [Related]
7. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.
Tatarek J; Cullion K; Ashworth T; Gerstein R; Aster JC; Kelliher MA
Blood; 2011 Aug; 118(6):1579-90. PubMed ID: 21670468
[TBL] [Abstract][Full Text] [Related]
8. Lmo2 and Scl/Tal1 convert non-axial mesoderm into haemangioblasts which differentiate into endothelial cells in the absence of Gata1.
Gering M; Yamada Y; Rabbitts TH; Patient RK
Development; 2003 Dec; 130(25):6187-99. PubMed ID: 14602685
[TBL] [Abstract][Full Text] [Related]
9. Building multifunctionality into a complex containing master regulators of hematopoiesis.
Fujiwara T; Lee HY; Sanalkumar R; Bresnick EH
Proc Natl Acad Sci U S A; 2010 Nov; 107(47):20429-34. PubMed ID: 21059912
[TBL] [Abstract][Full Text] [Related]
10. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice.
Larson RC; Lavenir I; Larson TA; Baer R; Warren AJ; Wadman I; Nottage K; Rabbitts TH
EMBO J; 1996 Mar; 15(5):1021-7. PubMed ID: 8605871
[TBL] [Abstract][Full Text] [Related]
11. TAL1 and LIM-only proteins synergistically induce retinaldehyde dehydrogenase 2 expression in T-cell acute lymphoblastic leukemia by acting as cofactors for GATA3.
Ono Y; Fukuhara N; Yoshie O
Mol Cell Biol; 1998 Dec; 18(12):6939-50. PubMed ID: 9819382
[TBL] [Abstract][Full Text] [Related]
12. Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL.
McCormack MP; Shields BJ; Jackson JT; Nasa C; Shi W; Slater NJ; Tremblay CS; Rabbitts TH; Curtis DJ
Blood; 2013 Sep; 122(12):2093-103. PubMed ID: 23926305
[TBL] [Abstract][Full Text] [Related]
13. NKX3.1 is a direct TAL1 target gene that mediates proliferation of TAL1-expressing human T cell acute lymphoblastic leukemia.
Kusy S; Gerby B; Goardon N; Gault N; Ferri F; Gérard D; Armstrong F; Ballerini P; Cayuela JM; Baruchel A; Pflumio F; Roméo PH
J Exp Med; 2010 Sep; 207(10):2141-56. PubMed ID: 20855495
[TBL] [Abstract][Full Text] [Related]
14. Angiopoietin-2 is a direct transcriptional target of TAL1, LYL1 and LMO2 in endothelial cells.
Deleuze V; El-Hajj R; Chalhoub E; Dohet C; Pinet V; Couttet P; Mathieu D
PLoS One; 2012; 7(7):e40484. PubMed ID: 22792348
[TBL] [Abstract][Full Text] [Related]
15. A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients.
Oram SH; Thoms JA; Pridans C; Janes ME; Kinston SJ; Anand S; Landry JR; Lock RB; Jayaraman PS; Huntly BJ; Pimanda JE; Göttgens B
Oncogene; 2010 Oct; 29(43):5796-808. PubMed ID: 20676125
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional activity of TAL1 in T cell acute lymphoblastic leukemia (T-ALL) requires RBTN1 or -2 and induces TALLA1, a highly specific tumor marker of T-ALL.
Ono Y; Fukuhara N; Yoshie O
J Biol Chem; 1997 Feb; 272(7):4576-81. PubMed ID: 9020185
[TBL] [Abstract][Full Text] [Related]
17. SCL assembles a multifactorial complex that determines glycophorin A expression.
Lahlil R; Lécuyer E; Herblot S; Hoang T
Mol Cell Biol; 2004 Feb; 24(4):1439-52. PubMed ID: 14749362
[TBL] [Abstract][Full Text] [Related]
18. FOXP3 can modulate TAL1 transcriptional activity through interaction with LMO2.
Fleskens V; Mokry M; van der Leun AM; Huppelschoten S; Pals CE; Peeters J; Coenen S; Cardoso BA; Barata JT; van Loosdregt J; Coffer PJ
Oncogene; 2016 Aug; 35(31):4141-8. PubMed ID: 26686090
[TBL] [Abstract][Full Text] [Related]
19. The LIM-domain binding protein Ldb1 and its partner LMO2 act as negative regulators of erythroid differentiation.
Visvader JE; Mao X; Fujiwara Y; Hahm K; Orkin SH
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13707-12. PubMed ID: 9391090
[TBL] [Abstract][Full Text] [Related]
20. A positive role for NLI/Ldb1 in long-range beta-globin locus control region function.
Song SH; Hou C; Dean A
Mol Cell; 2007 Dec; 28(5):810-22. PubMed ID: 18082606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]